Inhibikase Therapeutics ( (IKT) ) has provided an announcement.
Inhibikase Therapeutics, Inc. released a new presentation on their website detailing the development of disease-modifying therapeutics for Pulmonary Arterial Hypertension (PAH). The company’s multi-therapeutic pipeline includes IkT-001Pro, a prodrug of imatinib mesylate with a significant market potential, and Risvodetinib for untreated Parkinson’s disease, with Phase 2 results expected soon. The presentation underscores the high unmet need for new PAH treatments and highlights the potential of imatinib, which has shown disease-modifying properties but was previously unapproved due to serious adverse events that the company aims to mitigate.
See more insights into IKT stock on TipRanks’ Stock Analysis page.
